Moreover, compared with Paxlovid, which has strict requirements for drugs involving the CYP3A metabolic pathway, while basic disease drugs does not need to be stopped when taking YDJDG, making YDJDG an important and safe choice for patients with various serious basic diseases and severe liver and kidney function damage(Liu et al., 2020a). This evidence concerns the gene CYP3A4 and glycogen storage disease VI.